Trial result ·
Long-Term Hematologic Effects of Selumetinib Treatment in Children With Neurofibromatosis Type 1-Associated Plexiform Neurofibromas.
Written based on 1 research study on PubMed, searched on 3 Nov 2026.
What was studied
This study looked at blood effects of selumetinib in children. The children had neurofibromatosis type 1 with inoperable plexiform neurofibromas. Selumetinib is a mitogen-activated protein kinase kinase inhibitor. It was the first drug approved by the Food and Drug Administration for these tumors. 98 children came from the SPRINT trial. Median follow-up was 5.1 years. It ranged from 0.2 to 11 years. The study checked blood counts over time.
What they found
The large majority of values stayed within normal limits across timepoints. This held for white blood cell, platelet, neutrophil and lymphocyte counts. Lymphocyte count fell and mean corpuscular volume rose. These changes were statistically significant. They were unlikely to be clinically significant.
What it means for patients
The authors say selumetinib was not linked to clinically significant blood changes. They say the changes seen were unlikely to matter clinically.
Why it is not certain yet
The abstract describes no comparison group. The data came from one trial of 98 children. Follow-up times varied widely. The abstract does not give counts of side effects. Only blood effects were checked here. The changes were statistically significant but judged unlikely to matter.
The registered trial
The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.
Source
Long-Term Hematologic Effects of Selumetinib Treatment in Children With Neurofibromatosis Type 1-Associated Plexiform Neurofibromas.
PubMed · PMID 42527881We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Neurofibromatosis type 1 publications